Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.

This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had receive...

Descripción completa

Detalles Bibliográficos
Autores: Martinez-Cuadron, D, Serrano, J, Mariz, J, Gil, C, Tormo, M, Martinez-Sanchez, P, Rodriguez-Arboli, E, Garcia-Boyero, R, Rodriguez-Medina, C, Martinez-Chamorro, C, Polo, M, Bergua, J, Aguiar, E, Amigo, ML, Herrera, P, Alonso-Dominguez, JM, Bernal, T, Espadana, A, Sayas, MJ, Algarra, L, Vidriales, MB, Vasconcelos, G, Vives, S, Perez-Encinas, MM, Lopez, A, Noriega, V, Garcia-Fortes, M, Chillon, MC, Rodriguez-Gutierrez, JI, Calasanz, MJ, Labrador, J, Lopez, JA, Boluda, B, Rodriguez-Veiga, R, Martinez-Lopez, J, Barragan, E, Sanz, MA, Montesinos, P
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16618
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/16618
Access Level:acceso abierto
Palabra clave:FLT3-ITD mutation
acute myeloid leukemia
real-world outcomes
relapsed/refractory disease
salvage therapy
Descripción
Sumario:This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.

Similares en LA Referencia